Method for treating glioblastoma using antibodies binding to the extracellular domain of the receptor tyrosine kinase ALK
US8945563B2 · kind B2 · utility
2Cited by
8References
16Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 31, 2011 |
| Grant date | Feb 3, 2015 |
| Priority date | — |
| Expiry date | Dec 6, 2033 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Y207/10001
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention concerns an antibody specific for human ALK (Anaplastic Lymphoma Kinase), in particular a scFv, a nucleic acid sequence encoding it, its production and its use as a pharmaceutical or for diagnostic purposes. Said antibody is suitable for the local treatment of tumors, in particular glioblastoma.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.